Alvotech (NASDAQ:ALVOW) Short Interest Update

Alvotech (NASDAQ:ALVOW) was the target of a significant drop in short interest in March. As of March 15th, there was short interest totalling 6,000 shares, a drop of 36.2% from the February 28th total of 9,400 shares. Based on an average trading volume of 10,200 shares, the days-to-cover ratio is presently 0.6 days.

Alvotech Stock Down 16.6 %

Shares of NASDAQ:ALVOW opened at $1.56 on Monday. Alvotech has a 1 year low of $1.16 and a 1 year high of $4.99. The business’s 50 day moving average price is $2.29 and its 200-day moving average price is $2.71.

Alvotech Company Profile

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass.